<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36834792</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Aggregation of Disordered Proteins Associated with Neurodegeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3380</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24043380</ELocationID><Abstract><AbstractText>Cellular deposition of protein aggregates, one of the hallmarks of neurodegeneration, disrupts cellular functions and leads to neuronal death. Mutations, posttranslational modifications, and truncations are common molecular underpinnings in the formation of aberrant protein conformations that seed aggregation. The major proteins involved in neurodegeneration include amyloid beta (A&#x3b2;) and tau in Alzheimer's disease, &#x3b1;-synuclein in Parkinson's disease, and TAR DNA-binding protein (TDP-43) in amyotrophic lateral sclerosis (ALS). These proteins are described as intrinsically disordered and possess enhanced ability to partition into biomolecular condensates. In this review, we discuss the role of protein misfolding and aggregation in neurodegenerative diseases, specifically highlighting implications of changes to the primary/secondary (mutations, posttranslational modifications, and truncations) and the quaternary/supramolecular (oligomerization and condensation) structural landscapes for the four aforementioned proteins. Understanding these aggregation mechanisms provides insights into neurodegenerative diseases and their common underlying molecular pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsoi</LastName><ForeName>Phoebe S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quan</LastName><ForeName>My Diem</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreon</LastName><ForeName>Josephine C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreon</LastName><ForeName>Allan Chris M</ForeName><Initials>ACM</Initials><Identifier Source="ORCID">0000-0002-8538-1732</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS105874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS107792</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS109678</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM122763</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064267">Intrinsically Disordered Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064267" MajorTopicYN="Y">Intrinsically Disordered Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AlphaFold</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">LLPS</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">biomolecular condensates</Keyword><Keyword MajorTopicYN="N">intrinsically disordered proteins</Keyword><Keyword MajorTopicYN="N">liquid&#x2013;liquid phase separation</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">&#x3b1;-synuclein</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>2</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36834792</ArticleId><ArticleId IdType="pmc">PMC9966039</ArticleId><ArticleId IdType="doi">10.3390/ijms24043380</ArticleId><ArticleId IdType="pii">ijms24043380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kovacs G.G. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int. J. Mol. Sci. 2016;17:189. doi: 10.3390/ijms17020189.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17020189</ArticleId><ArticleId IdType="pmc">PMC4783923</ArticleId><ArticleId IdType="pubmed">26848654</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky V.N., Gillespie J.R., Fink A.L. Why are &#x201c;natively unfolded&#x201d; proteins unstructured under physiologic conditions? Proteins. 2000;41:415&#x2013;427. doi: 10.1002/1097-0134(20001115)41:3&lt;415::AID-PROT130&gt;3.0.CO;2-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0134(20001115)41:3&lt;415::AID-PROT130&gt;3.0.CO;2-7</ArticleId><ArticleId IdType="pubmed">11025552</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman-Kay J.D., Mittag T. From sequence and forces to structure, function, and evolution of intrinsically disordered proteins. Structure. 2013;21:1492&#x2013;1499. doi: 10.1016/j.str.2013.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2013.08.001</ArticleId><ArticleId IdType="pmc">PMC4704097</ArticleId><ArticleId IdType="pubmed">24010708</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyson H.J., Wright P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 2005;6:197&#x2013;208. doi: 10.1038/nrm1589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1589</ArticleId><ArticleId IdType="pubmed">15738986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei G., Xi W., Nussinov R., Ma B. Protein Ensembles: How Does Nature Harness Thermodynamic Fluctuations for Life? The Diverse Functional Roles of Conformational Ensembles in the Cell. Chem. Rev. 2016;116:6516&#x2013;6551. doi: 10.1021/acs.chemrev.5b00562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.5b00562</ArticleId><ArticleId IdType="pmc">PMC6407618</ArticleId><ArticleId IdType="pubmed">26807783</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh J.A., Forman-Kay J.D. Sequence determinants of compaction in intrinsically disordered proteins. Biophys. J. 2010;98:2383&#x2013;2390. doi: 10.1016/j.bpj.2010.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2010.02.006</ArticleId><ArticleId IdType="pmc">PMC2872267</ArticleId><ArticleId IdType="pubmed">20483348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao A.H., Crick S.L., Vitalis A., Chicoine C.L., Pappu R.V. Net charge per residue modulates conformational ensembles of intrinsically disordered proteins. Proc. Natl. Acad. Sci. USA. 2010;107:8183&#x2013;8188. doi: 10.1073/pnas.0911107107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911107107</ArticleId><ArticleId IdType="pmc">PMC2889596</ArticleId><ArticleId IdType="pubmed">20404210</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller-Spath S., Soranno A., Hirschfeld V., Hofmann H., Ruegger S., Reymond L., Nettels D., Schuler B. From the Cover: Charge interactions can dominate the dimensions of intrinsically disordered proteins. Proc. Natl. Acad. Sci. USA. 2010;107:14609&#x2013;14614. doi: 10.1073/pnas.1001743107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1001743107</ArticleId><ArticleId IdType="pmc">PMC2930438</ArticleId><ArticleId IdType="pubmed">20639465</ArticleId></ArticleIdList></Reference><Reference><Citation>Shammas S.L. Mechanistic roles of protein disorder within transcription. Curr. Opin. Struct. Biol. 2017;42:155&#x2013;161. doi: 10.1016/j.sbi.2017.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2017.02.003</ArticleId><ArticleId IdType="pubmed">28262589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsafou K., Tiwari P.B., Forman-Kay J.D., Metallo S.J., Toretsky J.A. Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm. J. Mol. Biol. 2018;430:2321&#x2013;2341. doi: 10.1016/j.jmb.2018.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2018.04.008</ArticleId><ArticleId IdType="pubmed">29655986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon M.K., Mitrea D.M., Ou L., Kriwacki R.W. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem. Soc. Trans. 2012;40:981&#x2013;988. doi: 10.1042/BST20120092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120092</ArticleId><ArticleId IdType="pmc">PMC7065656</ArticleId><ArticleId IdType="pubmed">22988851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondos S.E., Dunker A.K., Uversky V.N. On the roles of intrinsically disordered proteins and regions in cell communication and signaling. Cell Commun. Signal. 2021;19:88. doi: 10.1186/s12964-021-00774-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-021-00774-3</ArticleId><ArticleId IdType="pmc">PMC8404256</ArticleId><ArticleId IdType="pubmed">34461937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright P.E., Dyson H.J. Intrinsically disordered proteins in cellular signalling and regulation. Nat. Rev. Mol. Cell Biol. 2015;16:18&#x2013;29. doi: 10.1038/nrm3920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3920</ArticleId><ArticleId IdType="pmc">PMC4405151</ArticleId><ArticleId IdType="pubmed">25531225</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield C.J., Dunker A.K. Intrinsically disordered proteins and intrinsically disordered protein regions. Annu. Rev. Biochem. 2014;83:553&#x2013;584. doi: 10.1146/annurev-biochem-072711-164947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-072711-164947</ArticleId><ArticleId IdType="pubmed">24606139</ArticleId></ArticleIdList></Reference><Reference><Citation>Radivojac P., Iakoucheva L.M., Oldfield C.J., Obradovic Z., Uversky V.N., Dunker A.K. Intrinsic disorder and functional proteomics. Biophys. J. 2007;92:1439&#x2013;1456. doi: 10.1529/biophysj.106.094045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.106.094045</ArticleId><ArticleId IdType="pmc">PMC1796814</ArticleId><ArticleId IdType="pubmed">17158572</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 2003;81:678&#x2013;699. doi: 10.1007/s00109-003-0464-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-003-0464-5</ArticleId><ArticleId IdType="pubmed">12942175</ArticleId></ArticleIdList></Reference><Reference><Citation>Breydo L., Redington J.M., Uversky V.N. Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins. Int. Rev. Cell Mol. Biol. 2017;329:145&#x2013;185. doi: 10.1016/bs.ircmb.2016.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ircmb.2016.08.011</ArticleId><ArticleId IdType="pubmed">28109327</ArticleId></ArticleIdList></Reference><Reference><Citation>Candelise N., Scaricamazza S., Salvatori I., Ferri A., Valle C., Manganelli V., Garofalo T., Sorice M., Misasi R. Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications. Int. J. Mol. Sci. 2021;22:6016. doi: 10.3390/ijms22116016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116016</ArticleId><ArticleId IdType="pmc">PMC8199687</ArticleId><ArticleId IdType="pubmed">34199513</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C., Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 2018;21:1332&#x2013;1340. doi: 10.1038/s41593-018-0235-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId><ArticleId IdType="pmc">PMC6432913</ArticleId><ArticleId IdType="pubmed">30250260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hromadkova L., Siddiqi M.K., Liu H., Safar J.G. Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer&#x2019;s Disease and Related Dementias. Cells. 2022;11:2997. doi: 10.3390/cells11192997.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11192997</ArticleId><ArticleId IdType="pmc">PMC9562632</ArticleId><ArticleId IdType="pubmed">36230957</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes C.M., Titus E.A., Cooper A.A. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol. Cell. 2004;15:767&#x2013;776. doi: 10.1016/j.molcel.2004.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2004.08.025</ArticleId><ArticleId IdType="pubmed">15350220</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Kaneko K., Matsumoto G., Kurosawa M., Nukina N. Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J. Neurosci. 2009;29:5153&#x2013;5162. doi: 10.1523/JNEUROSCI.0783-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0783-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665470</ArticleId><ArticleId IdType="pubmed">19386911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim K.H. Diverse Misfolded Conformational Strains and Cross-seeding of Misfolded Proteins Implicated in Neurodegenerative Diseases. Front. Mol. Neurosci. 2019;12:158. doi: 10.3389/fnmol.2019.00158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00158</ArticleId><ArticleId IdType="pmc">PMC6629833</ArticleId><ArticleId IdType="pubmed">31338019</ArticleId></ArticleIdList></Reference><Reference><Citation>Subedi S., Sasidharan S., Nag N., Saudagar P., Tripathi T. Amyloid Cross-Seeding: Mechanism, Implication, and Inhibition. Molecules. 2022;27:1776. doi: 10.3390/molecules27061776.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27061776</ArticleId><ArticleId IdType="pmc">PMC8955620</ArticleId><ArticleId IdType="pubmed">35335141</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales R., Moreno-Gonzalez I., Soto C. Cross-seeding of misfolded proteins: Implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013;9:e1003537. doi: 10.1371/journal.ppat.1003537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003537</ArticleId><ArticleId IdType="pmc">PMC3777858</ArticleId><ArticleId IdType="pubmed">24068917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Zidek A., Potapenko A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583&#x2013;589. doi: 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosztanyi Z. Prediction of protein disorder based on IUPred. Protein Sci. 2018;27:331&#x2013;340. doi: 10.1002/pro.3334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3334</ArticleId><ArticleId IdType="pmc">PMC5734386</ArticleId><ArticleId IdType="pubmed">29076577</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosztanyi Z., Csizmok V., Tompa P., Simon I. The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins. J. Mol. Biol. 2005;347:827&#x2013;839. doi: 10.1016/j.jmb.2005.01.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.01.071</ArticleId><ArticleId IdType="pubmed">15769473</ArticleId></ArticleIdList></Reference><Reference><Citation>Meszaros B., Erdos G., Dosztanyi Z. IUPred2A: Context-dependent prediction of protein disorder as a function of redox state and protein binding. Nucleic Acids Res. 2018;46:W329&#x2013;W337. doi: 10.1093/nar/gky384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky384</ArticleId><ArticleId IdType="pmc">PMC6030935</ArticleId><ArticleId IdType="pubmed">29860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Meszaros B., Simon I., Dosztanyi Z. Prediction of protein binding regions in disordered proteins. PLoS Comput. Biol. 2009;5:e1000376. doi: 10.1371/journal.pcbi.1000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1000376</ArticleId><ArticleId IdType="pmc">PMC2671142</ArticleId><ArticleId IdType="pubmed">19412530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreon A.C., Gambin Y., Lemke E.A., Deniz A.A. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc. Natl. Acad. Sci. USA. 2009;106:5645&#x2013;5650. doi: 10.1073/pnas.0809232106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0809232106</ArticleId><ArticleId IdType="pmc">PMC2667048</ArticleId><ArticleId IdType="pubmed">19293380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreon A.C., Deniz A.A. Alpha-synuclein multistate folding thermodynamics: Implications for protein misfolding and aggregation. Biochemistry. 2007;46:4499&#x2013;4509. doi: 10.1021/bi602461y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi602461y</ArticleId><ArticleId IdType="pubmed">17378587</ArticleId></ArticleIdList></Reference><Reference><Citation>Trexler A.J., Rhoades E. Alpha-synuclein binds large unilamellar vesicles as an extended helix. Biochemistry. 2009;48:2304&#x2013;2306. doi: 10.1021/bi900114z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi900114z</ArticleId><ArticleId IdType="pmc">PMC2837115</ArticleId><ArticleId IdType="pubmed">19220042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cras P., van Harskamp F., Hendriks L., Ceuterick C., van Duijn C.M., Stefanko S.Z., Hofman A., Kros J.M., Van Broeckhoven C., Martin J.J. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala--&gt;Gly mutation. Acta Neuropathol. 1998;96:253&#x2013;260. doi: 10.1007/s004010050892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050892</ArticleId><ArticleId IdType="pubmed">9754958</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrow C.J., Yasuda A., Kenny P.T., Zagorski M.G. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer&#x2019;s disease. Analysis of circular dichroism spectra. J. Mol. Biol. 1992;225:1075&#x2013;1093. doi: 10.1016/0022-2836(92)90106-T.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(92)90106-T</ArticleId><ArticleId IdType="pubmed">1613791</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatafta H., Khaled M., Owen M.C., Sayyed-Ahmad A., Strodel B. Amyloid-beta peptide dimers undergo a random coil to beta-sheet transition in the aqueous phase but not at the neuronal membrane. Proc. Natl. Acad. Sci. USA. 2021;118:e2106210118. doi: 10.1073/pnas.2106210118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2106210118</ArticleId><ArticleId IdType="pmc">PMC8488611</ArticleId><ArticleId IdType="pubmed">34544868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663&#x2013;672. doi: 10.1038/nrn2194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526. doi: 10.1016/0896-6273(89)90210-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047. doi: 10.1126/science.276.5321.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5321.2045</ArticleId><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004;10((Suppl. S7)):S10&#x2013;S17. doi: 10.1038/nm1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1066</ArticleId><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003;4:49&#x2013;60. doi: 10.1038/nrn1007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1007</ArticleId><ArticleId IdType="pubmed">12511861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Rosa-Neto P., Hsiung G.Y., Sadovnick A.D., Masellis M., Black S.E., Jia J., Gauthier S. Early-onset familial Alzheimer&#x2019;s disease (EOFAD) Can. J. Neurol. Sci. 2012;39:436&#x2013;445. doi: 10.1017/S0317167100013949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100013949</ArticleId><ArticleId IdType="pubmed">22728850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran J., Anastacio H., Bardy C. Genetic predispositions of Parkinson&#x2019;s disease revealed in patient-derived brain cells. NPJ Park. Dis. 2020;6:8. doi: 10.1038/s41531-020-0110-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-020-0110-8</ArticleId><ArticleId IdType="pmc">PMC7181694</ArticleId><ArticleId IdType="pubmed">32352027</ArticleId></ArticleIdList></Reference><Reference><Citation>Emery A.E., Holloway S. Familial motor neuron diseases. Adv. Neurol. 1982;36:139&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">7180680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N., David J.P., Lefranc D., Vermersch P., Wattez A., Delacourte A. Different distribution of phosphorylated tau protein isoforms in Alzheimer&#x2019;s and Pick&#x2019;s diseases. FEBS Lett. 1997;412:578&#x2013;582. doi: 10.1016/S0014-5793(97)00859-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(97)00859-4</ArticleId><ArticleId IdType="pubmed">9276470</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford P.M., Halliday G.M., Brooks W.S., Kwok J.B., Storey C.E., Creasey H., Morris J.G., Fulham M.J., Schofield P.R. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations. Pt 5Brain. 2000;123:880&#x2013;893. doi: 10.1093/brain/123.5.880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.5.880</ArticleId><ArticleId IdType="pubmed">10775534</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional Significance of TDP-43 Mutations in Disease. Adv. Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin T.C., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A.L., Lu M., Fu Y., Garcia-Sierra F., LaPointe N., et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2003;100:10032&#x2013;10037. doi: 10.1073/pnas.1630428100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1630428100</ArticleId><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Tanzi R.E. The genetics of Alzheimer&#x2019;s disease. Prog. Mol. Biol. Transl. Sci. 2012;107:79&#x2013;100. doi: 10.1016/B978-0-12-385883-2.00008-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385883-2.00008-4</ArticleId><ArticleId IdType="pubmed">22482448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino Z.A., Giasson B.I. The emerging role of alpha-synuclein truncation in aggregation and disease. J. Biol. Chem. 2020;295:10224&#x2013;10244. doi: 10.1074/jbc.REV120.011743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.REV120.011743</ArticleId><ArticleId IdType="pmc">PMC7383394</ArticleId><ArticleId IdType="pubmed">32424039</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012;33:1340&#x2013;1344. doi: 10.1002/humu.22117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22117</ArticleId><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., et al. The &#x2018;Arctic&#x2019; APP mutation (E693G) causes Alzheimer&#x2019;s disease by enhanced Abeta protofibril formation. Nat. Neurosci. 2001;4:887&#x2013;893. doi: 10.1038/nn0901-887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0901-887</ArticleId><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch K.M., DeVos S.L., Miller R.L., Chun S.J., Norrbom M., Wozniak D.F., Dawson H.N., Bennett C.F., Rigo F., Miller T.M. Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron. 2016;90:941&#x2013;947. doi: 10.1016/j.neuron.2016.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.042</ArticleId><ArticleId IdType="pmc">PMC5040069</ArticleId><ArticleId IdType="pubmed">27210553</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J. Alzheimer&#x2019;s disease: Genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766. doi: 10.1152/physrev.2001.81.2.741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2001.81.2.741</ArticleId><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli B.V., Mohapatra G., Mattheisen M., Parrado A.R., Roehr J.T., Shen Y., Gusella J.F., Moir R., Saunders A.J., Lange C., et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology. 2012;78:1250&#x2013;1257. doi: 10.1212/WNL.0b013e3182515972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182515972</ArticleId><ArticleId IdType="pmc">PMC3324321</ArticleId><ArticleId IdType="pubmed">22491860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlin C., Lord A., Magnusson K., Englund H., Almeida C.G., Greengard P., Nyberg F., Gouras G.K., Lannfelt L., Nilsson L.N. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J. Neurochem. 2007;101:854&#x2013;862. doi: 10.1111/j.1471-4159.2006.04443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04443.x</ArticleId><ArticleId IdType="pubmed">17448150</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A.S., Berglind-Dehlin F., Karlsson G., Edwards K., Gellerfors P., Lannfelt L. Physiochemical characterization of the Alzheimer&#x2019;s disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J. 2006;273:2618&#x2013;2630. doi: 10.1111/j.1742-4658.2006.05263.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2006.05263.x</ArticleId><ArticleId IdType="pubmed">16817891</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M., Jakes R., Edwards P.C., Milstein C., Wischik C.M. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc. Natl. Acad. Sci. USA. 1991;88:5837&#x2013;5841. doi: 10.1073/pnas.88.13.5837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.13.5837</ArticleId><ArticleId IdType="pmc">PMC51973</ArticleId><ArticleId IdType="pubmed">1712107</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A.D., Cohen L.S., Corbo C., Morozova V., ElIdrissi A., Phillips G., Kleiman F.E. Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability. Front. Cell. Neurosci. 2018;12:338. doi: 10.3389/fncel.2018.00338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00338</ArticleId><ArticleId IdType="pmc">PMC6189415</ArticleId><ArticleId IdType="pubmed">30356756</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998;43:815&#x2013;825. doi: 10.1002/ana.410430617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430617</ArticleId><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Murrell J.R., Goedert M., Farlow M., Klug A., Ghetti B. Mutations in the tau gene (MAPT) in FTDP-17: The family with Multiple System Tauopathy with Presenile Dementia (MSTD) J. Alzheimers Dis. 2006;9:373&#x2013;380. doi: 10.3233/JAD-2006-9S342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2006-9S342</ArticleId><ArticleId IdType="pubmed">16914875</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinueza-Gavilanes R., Inigo-Marco I., Larrea L., Lasa M., Carte B., Santamaria E., Fernandez-Irigoyen J., Bugallo R., Aragon T., Aldabe R., et al. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity. Neurobiol. Dis. 2020;137:104781. doi: 10.1016/j.nbd.2020.104781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104781</ArticleId><ArticleId IdType="pubmed">31991248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004;55:164&#x2013;173. doi: 10.1002/ana.10795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10795</ArticleId><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson&#x2019;s disease. Nat. Genet. 1998;18:106&#x2013;108. doi: 10.1038/ng0298-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0298-106</ArticleId><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Robotta M., Cattani J., Martins J.C., Subramaniam V., Drescher M. Alpha-Synuclein Disease Mutations Are Structurally Defective and Locally Affect Membrane Binding. J. Am. Chem. Soc. 2017;139:4254&#x2013;4257. doi: 10.1021/jacs.6b05335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b05335</ArticleId><ArticleId IdType="pubmed">28298083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreon A.C., Moran C.R., Ferreon J.C., Deniz A.A. Alteration of the alpha-synuclein folding landscape by a mutation related to Parkinson&#x2019;s disease. Angew. Chem. Int. Ed. Engl. 2010;49:3469&#x2013;3472. doi: 10.1002/anie.201000378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201000378</ArticleId><ArticleId IdType="pmc">PMC2972640</ArticleId><ArticleId IdType="pubmed">20544898</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson&#x2019;s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry. 2001;40:11604&#x2013;11613. doi: 10.1021/bi010616g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi010616g</ArticleId><ArticleId IdType="pubmed">11560511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z., Krasnoslobodtsev A.V., Zhang Y., Ysselstein D., Rochet J.C., Blanchard S.C., Lyubchenko Y.L. Direct Detection of alpha-Synuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis. Biophys. J. 2015;108:2038&#x2013;2047. doi: 10.1016/j.bpj.2015.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2015.03.010</ArticleId><ArticleId IdType="pmc">PMC4407253</ArticleId><ArticleId IdType="pubmed">25902443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Jangir D.K., Kumar R., Kumari M., Bhavesh N.S., Maiti T.K. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced alpha-Synuclein Fibrillation and Cytotoxicity. ACS Chem. Neurosci. 2018;9:230&#x2013;240. doi: 10.1021/acschemneuro.6b00430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00430</ArticleId><ArticleId IdType="pubmed">28841377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A.K., Lin R.Y., Hsieh E.Z., Tu P.H., Chen R.P., Liao T.Y., Chen W., Wang C.H., Huang J.J. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J. Am. Chem. Soc. 2010;132:1186&#x2013;1187. doi: 10.1021/ja9066207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9066207</ArticleId><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Chen Y., Zhou X., Kar A., Ray P., Chen X., Rao E.J., Yang M., Ye H., Zhu L., et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Struct. Mol. Biol. 2011;18:822&#x2013;830. doi: 10.1038/nsmb.2053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2053</ArticleId><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S., Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2012;4:9. doi: 10.1186/alzrt107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt107</ArticleId><ArticleId IdType="pmc">PMC3334542</ArticleId><ArticleId IdType="pubmed">22494386</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso Adel C., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 2004;279:34873&#x2013;34881. doi: 10.1074/jbc.M405131200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M405131200</ArticleId><ArticleId IdType="pubmed">15190058</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau protein and neurodegeneration. Semin. Cell Dev. Biol. 2004;15:45&#x2013;49. doi: 10.1016/j.semcdb.2003.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2003.12.015</ArticleId><ArticleId IdType="pubmed">15036206</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasanen P., Myllykangas L., Siitonen M., Raunio A., Kaakkola S., Lyytinen J., Tienari P.J., Poyhonen M., Paetau A. Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson&#x2019;s disease-type pathology. Neurobiol. Aging. 2014;35:2180.e1&#x2013;2180.e5. doi: 10.1016/j.neurobiolaging.2014.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.03.024</ArticleId><ArticleId IdType="pubmed">24746362</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Y., Zhao X., Liu F., Yan S., Wang Y., Du C., Cui X., Li R., Zhang C.X. Pathogenic Mutations Differentially Regulate Cell-to-Cell Transmission of alpha-Synuclein. Front. Cell. Neurosci. 2020;14:159. doi: 10.3389/fncel.2020.00159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00159</ArticleId><ArticleId IdType="pmc">PMC7303300</ArticleId><ArticleId IdType="pubmed">32595456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Kametani F., Arai T., Akiyama H., Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum. Mol. Genet. 2009;18:3353&#x2013;3364. doi: 10.1093/hmg/ddp275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp275</ArticleId><ArticleId IdType="pubmed">19515851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bah A., Forman-Kay J.D. Modulation of Intrinsically Disordered Protein Function by Post-translational Modifications. J. Biol. Chem. 2016;291:6696&#x2013;6705. doi: 10.1074/jbc.R115.695056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R115.695056</ArticleId><ArticleId IdType="pmc">PMC4807257</ArticleId><ArticleId IdType="pubmed">26851279</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling A.L., Uversky V.N. Intrinsic Disorder and Posttranslational Modifications: The Darker Side of the Biological Dark Matter. Front. Genet. 2018;9:158. doi: 10.3389/fgene.2018.00158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00158</ArticleId><ArticleId IdType="pmc">PMC5945825</ArticleId><ArticleId IdType="pubmed">29780404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer&#x2019;s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089&#x2013;1099. doi: 10.1016/0896-6273(93)90057-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(93)90057-X</ArticleId><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Walter J. Phosphorylation of amyloid beta (Abeta) peptides&#x2014;A trigger for formation of toxic aggregates in Alzheimer&#x2019;s disease. Aging. 2011;3:803&#x2013;812. doi: 10.18632/aging.100362.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100362</ArticleId><ArticleId IdType="pmc">PMC3184981</ArticleId><ArticleId IdType="pubmed">21869458</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson J.E., Sengupta U., Lasagna-Reeves C.A., Guerrero-Munoz M.J., Troncoso J., Kayed R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2014;2:73. doi: 10.1186/2051-5960-2-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-73</ArticleId><ArticleId IdType="pmc">PMC4229782</ArticleId><ArticleId IdType="pubmed">24927818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Rezaei-Ghaleh N., Terwel D., Thal D.R., Richard M., Hoch M., Mc Donald J.M., Wullner U., Glebov K., Heneka M.T., et al. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer&#x2019;s disease. EMBO J. 2011;30:2255&#x2013;2265. doi: 10.1038/emboj.2011.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.138</ArticleId><ArticleId IdType="pmc">PMC3117653</ArticleId><ArticleId IdType="pubmed">21527912</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal Upadhaya A., Kosterin I., Kumar S., von Arnim C.A., Yamaguchi H., Fandrich M., Walter J., Thal D.R. Biochemical stages of amyloid-beta peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer&#x2019;s disease. Brain. 2014;137:887&#x2013;903. doi: 10.1093/brain/awt362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt362</ArticleId><ArticleId IdType="pubmed">24519982</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannuzzi C., Irace G., Sirangelo I. Differential effects of glycation on protein aggregation and amyloid formation. Front. Mol. Biosci. 2014;1:9. doi: 10.3389/fmolb.2014.00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2014.00009</ArticleId><ArticleId IdType="pmc">PMC4428487</ArticleId><ArticleId IdType="pubmed">25988150</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1994;91:4766&#x2013;4770. doi: 10.1073/pnas.91.11.4766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.11.4766</ArticleId><ArticleId IdType="pmc">PMC43869</ArticleId><ArticleId IdType="pubmed">8197133</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.H., Du L.L., Cheng X.S., Jiang X., Zhang Y., Lv B.L., Liu R., Wang J.Z., Zhou X.W. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis. 2013;4:e673. doi: 10.1038/cddis.2013.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.180</ArticleId><ArticleId IdType="pmc">PMC3698547</ArticleId><ArticleId IdType="pubmed">23764854</ArticleId></ArticleIdList></Reference><Reference><Citation>Halim A., Brinkmalm G., Ruetschi U., Westman-Brinkmalm A., Portelius E., Zetterberg H., Blennow K., Larson G., Nilsson J. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc. Natl. Acad. Sci. USA. 2011;108:11848&#x2013;11853. doi: 10.1073/pnas.1102664108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102664108</ArticleId><ArticleId IdType="pmc">PMC3141957</ArticleId><ArticleId IdType="pubmed">21712440</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Wei Q., Xia W., He C., Zhang Q., Huang L., Wang X., Sun Y., Ma Y., Zhang X., et al. O-Glycosylation Induces Amyloid-beta To Form New Fibril Polymorphs Vulnerable for Degradation. J. Am. Chem. Soc. 2021;143:20216&#x2013;20223. doi: 10.1021/jacs.1c08607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.1c08607</ArticleId><ArticleId IdType="pubmed">34841862</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J.H., Johnson G.V. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 2003;278:187&#x2013;193. doi: 10.1074/jbc.M206236200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M206236200</ArticleId><ArticleId IdType="pubmed">12409305</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase C., Stieler J.T., Arendt T., Holzer M. Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. Neurochem. 2004;88:1509&#x2013;1520. doi: 10.1046/j.1471-4159.2003.02287.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02287.x</ArticleId><ArticleId IdType="pubmed">15009652</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S.W., Cho S.H., Zhou Y., Schroeder S., Haroutunian V., Seeley W.W., Huang E.J., Shen Y., Masliah E., Mukherjee C., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953&#x2013;966. doi: 10.1016/j.neuron.2010.08.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.044</ArticleId><ArticleId IdType="pmc">PMC3035103</ArticleId><ArticleId IdType="pubmed">20869593</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M., Knudsen G.M., Maeda S., Trinidad J.C., Ioanoviciu A., Burlingame A.L., Mucke L. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 2015;18:1183&#x2013;1189. doi: 10.1038/nn.4067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4067</ArticleId><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Guo J.L., Hurtado D.E., Kwong L.K., Mills I.P., Trojanowski J.Q., Lee V.M. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2011;2:252. doi: 10.1038/ncomms1255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1255</ArticleId><ArticleId IdType="pmc">PMC3120096</ArticleId><ArticleId IdType="pubmed">21427723</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., Cohen T.J., Grossman M., Arnold S.E., Xie S.X., Lee V.M., Trojanowski J.Q. Acetylated tau, a novel pathological signature in Alzheimer&#x2019;s disease and other tauopathies. Brain. 2012;135:807&#x2013;818. doi: 10.1093/brain/aws013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws013</ArticleId><ArticleId IdType="pmc">PMC3286338</ArticleId><ArticleId IdType="pubmed">22366796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C., Grundke-Iqbal I., Iqbal K., Fried V.A., Smith H.T., Wisniewski H.M. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res. 1991;539:11&#x2013;18. doi: 10.1016/0006-8993(91)90681-K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)90681-K</ArticleId><ArticleId IdType="pubmed">1849776</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Titani K., Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron. 1993;10:1151&#x2013;1160. doi: 10.1016/0896-6273(93)90063-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(93)90063-W</ArticleId><ArticleId IdType="pubmed">8391280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J.M., Wong E.S., Kirkpatrick D.S., Pletnikova O., Ko H.S., Tay S.P., Ho M.W., Troncoso J., Gygi S.P., Lee M.K., et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum. Mol. Genet. 2008;17:431&#x2013;439. doi: 10.1093/hmg/ddm320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm320</ArticleId><ArticleId IdType="pubmed">17981811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C.A., Yue M., Lin W.L., Dickson D.W., Dunmore J.H., Lee W.C., Zehr C., West G., Cao S., Clark A.M., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 2006;26:6985&#x2013;6996. doi: 10.1523/JNEUROSCI.0746-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0746-06.2006</ArticleId><ArticleId IdType="pmc">PMC6673930</ArticleId><ArticleId IdType="pubmed">16807328</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., De Lucia M., McGowan E., Lewis J., Prihar G., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004;13:703&#x2013;714. doi: 10.1093/hmg/ddh083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh083</ArticleId><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002;4:160&#x2013;164. doi: 10.1038/ncb748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb748</ArticleId><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Periquet M., Wang X., Negro A., McLean P.J., Hyman B.T., Feany M.B. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Investig. 2009;119:3257&#x2013;3265. doi: 10.1172/JCI39088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI39088</ArticleId><ArticleId IdType="pmc">PMC2769182</ArticleId><ArticleId IdType="pubmed">19855133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V.M., Trojanowski J.Q., Mann D., Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 2002;277:49071&#x2013;49076. doi: 10.1074/jbc.M208046200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M208046200</ArticleId><ArticleId IdType="pubmed">12377775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.M., Jang W.H., Quezado M.M., Oh Y., Chung K.C., Junn E., Mouradian M.M. Proteasome inhibition induces alpha-synuclein SUMOylation and aggregate formation. J. Neurol. Sci. 2011;307:157&#x2013;161. doi: 10.1016/j.jns.2011.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.04.015</ArticleId><ArticleId IdType="pmc">PMC3129438</ArticleId><ArticleId IdType="pubmed">21641618</ArticleId></ArticleIdList></Reference><Reference><Citation>Rott R., Szargel R., Shani V., Hamza H., Savyon M., Abd Elghani F., Bandopadhyay R., Engelender S. SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation. Proc. Natl. Acad. Sci. USA. 2017;114:13176&#x2013;13181. doi: 10.1073/pnas.1704351114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1704351114</ArticleId><ArticleId IdType="pmc">PMC5740625</ArticleId><ArticleId IdType="pubmed">29180403</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 2008;118:777&#x2013;788. doi: 10.1172/JCI32806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI32806</ArticleId><ArticleId IdType="pmc">PMC2157565</ArticleId><ArticleId IdType="pubmed">18172548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Park K., Comer F., Hsieh-Wilson L.C., Saudek C.D., Hart G.W. Site-specific GlcNAcylation of human erythrocyte proteins: Potential biomarker(s) for diabetes. Diabetes. 2009;58:309&#x2013;317. doi: 10.2337/db08-0994.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db08-0994</ArticleId><ArticleId IdType="pmc">PMC2628603</ArticleId><ArticleId IdType="pubmed">18984734</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Kwong L.K., Lee E.B., Kremmer E., Flatley A., Xu Y., Forman M.S., Troost D., Kretzschmar H.A., Trojanowski J.Q., et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Arai T., Buratti E., Baralle F.E., Akiyama H., Hasegawa M. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett. 2009;583:394&#x2013;400. doi: 10.1016/j.febslet.2008.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.12.031</ArticleId><ArticleId IdType="pubmed">19111550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Suzuki G., Tanaka Y., Kametani F., Hirai S., Okado H., Miyashita T., Saitoe M., Akiyama H., Masai H., et al. Phosphorylation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Truncated Casein Kinase 1delta Triggers Mislocalization and Accumulation of TDP-43. J. Biol. Chem. 2016;291:5473&#x2013;5483. doi: 10.1074/jbc.M115.695379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695379</ArticleId><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebron M.L., Lonskaya I., Sharpe K., Weerasinghe P.P., Algarzae N.K., Shekoyan A.R., Moussa C.E. Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6) J. Biol. Chem. 2013;288:4103&#x2013;4115. doi: 10.1074/jbc.M112.419945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.419945</ArticleId><ArticleId IdType="pmc">PMC3567661</ArticleId><ArticleId IdType="pubmed">23258539</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried N.T., Gozal Y.M., Dammer E.B., Xia Q., Duong D.M., Cheng D., Lah J.J., Levey A.I., Peng J. Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol. Cell. Proteom. 2010;9:705&#x2013;718. doi: 10.1074/mcp.M800390-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M800390-MCP200</ArticleId><ArticleId IdType="pmc">PMC2860236</ArticleId><ArticleId IdType="pubmed">20047951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Hwang A.W., Restrepo C.R., Yuan C.X., Trojanowski J.Q., Lee V.M. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 2015;6:5845. doi: 10.1038/ncomms6845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6845</ArticleId><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer M.P., Heneka M.T. Truncated and modified amyloid-beta species. Alzheimers Res. Ther. 2014;6:28. doi: 10.1186/alzrt258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt258</ArticleId><ArticleId IdType="pmc">PMC4055046</ArticleId><ArticleId IdType="pubmed">25031638</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzanza N.O., Sedlackova L., Kalaria R.N. Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders. Front. Aging Neurosci. 2021;13:690293. doi: 10.3389/fnagi.2021.690293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.690293</ArticleId><ArticleId IdType="pmc">PMC8267936</ArticleId><ArticleId IdType="pubmed">34248606</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C., Arya S., Kao A.W. Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation. Front. Neurol. 2020;11:595532. doi: 10.3389/fneur.2020.595532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.595532</ArticleId><ArticleId IdType="pmc">PMC7817643</ArticleId><ArticleId IdType="pubmed">33488497</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Li X., Li J.D. The Roles of Post-translational Modifications on alpha-Synuclein in the Pathogenesis of Parkinson&#x2019;s Diseases. Front. Neurosci. 2019;13:381. doi: 10.3389/fnins.2019.00381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00381</ArticleId><ArticleId IdType="pmc">PMC6482271</ArticleId><ArticleId IdType="pubmed">31057362</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacech B., Skrabana R., Novak M. Transition of tau protein from disordered to misordered in Alzheimer&#x2019;s disease. Neurodegener. Dis. 2010;7:24&#x2013;27. doi: 10.1159/000283478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000283478</ArticleId><ArticleId IdType="pubmed">20160453</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin S.G. The role of A beta 42 in Alzheimer&#x2019;s disease. J. Physiol. Paris. 1998;92:289&#x2013;292. doi: 10.1016/S0928-4257(98)80035-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0928-4257(98)80035-1</ArticleId><ArticleId IdType="pubmed">9789825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Yang C., Zhang X., Li Y., Wang S., Zheng L., Huang K. C-terminal truncation exacerbates the aggregation and cytotoxicity of alpha-Synuclein: A vicious cycle in Parkinson&#x2019;s disease. Biochim. Biophys. Acta Mol. Basis Dis. 2018;1864:3714&#x2013;3725. doi: 10.1016/j.bbadis.2018.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.10.003</ArticleId><ArticleId IdType="pubmed">30290273</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer&#x2019;s disease. Annu. Rev. Neurosci. 2011;34:185&#x2013;204. doi: 10.1146/annurev-neuro-061010-113613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-061010-113613</ArticleId><ArticleId IdType="pmc">PMC3174086</ArticleId><ArticleId IdType="pubmed">21456963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer&#x2019;s disease. Mol. Brain. 2011;4:3. doi: 10.1186/1756-6606-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-4-3</ArticleId><ArticleId IdType="pmc">PMC3022812</ArticleId><ArticleId IdType="pubmed">21214928</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Klafki H.W., Sparbier K., Smirnov A., Cepek L., Trenkwalder C., Ruther E., et al. CSF amyloid-beta-peptides in Alzheimer&#x2019;s disease, dementia with Lewy bodies and Parkinson&#x2019;s disease dementia. Brain. 2006;129:1177&#x2013;1187. doi: 10.1093/brain/awl063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl063</ArticleId><ArticleId IdType="pmc">PMC5403412</ArticleId><ArticleId IdType="pubmed">16600985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M., Mollenhauer B., Lewczuk P., Esselmann H., Wolf S., Trenkwalder C., Otto M., Stiens G., Ruther E., Kornhuber J., et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry. 2007;12:671&#x2013;680. doi: 10.1038/sj.mp.4001967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001967</ArticleId><ArticleId IdType="pubmed">17339876</ArticleId></ArticleIdList></Reference><Reference><Citation>Welge V., Fiege O., Lewczuk P., Mollenhauer B., Esselmann H., Klafki H.W., Wolf S., Trenkwalder C., Otto M., Kornhuber J., et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer&#x2019;s disease. J. Neural. Transm. 2009;116:203&#x2013;212. doi: 10.1007/s00702-008-0177-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-008-0177-6</ArticleId><ArticleId IdType="pubmed">19142572</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W., Huang Q., Wang Y., Wang Z.Y., Yao Y.Y. Assessment of CSF Abeta42 as an aid to discriminating Alzheimer&#x2019;s disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. J. Neurol. Sci. 2014;345:26&#x2013;36. doi: 10.1016/j.jns.2014.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.07.015</ArticleId><ArticleId IdType="pubmed">25086857</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirmalraj P.N., List J., Battacharya S., Howe G., Xu L., Thompson D., Mayer M. Complete aggregation pathway of amyloid beta (1-40) and (1-42) resolved on an atomically clean interface. Sci. Adv. 2020;6:eaaz6014. doi: 10.1126/sciadv.aaz6014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz6014</ArticleId><ArticleId IdType="pmc">PMC7141833</ArticleId><ArticleId IdType="pubmed">32285004</ArticleId></ArticleIdList></Reference><Reference><Citation>Asami-Odaka A., Ishibashi Y., Kikuchi T., Kitada C., Suzuki N. Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry. 1995;34:10272&#x2013;10278. doi: 10.1021/bi00032a022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00032a022</ArticleId><ArticleId IdType="pubmed">7640283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Kotilinek L.A., Smith B., Hlynialuk C., Zahs K., Ramsden M., Cleary J., Ashe K.H. Caspase-2 cleavage of tau reversibly impairs memory. Nat. Med. 2016;22:1268&#x2013;1276. doi: 10.1038/nm.4199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4199</ArticleId><ArticleId IdType="pubmed">27723722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman R.A., Poon W.W., Blurton-Jones M., Oddo S., Torp R., Vitek M.P., LaFerla F.M., Rohn T.T., Cotman C.W. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Investig. 2004;114:121&#x2013;130. doi: 10.1172/JCI200420640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200420640</ArticleId><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Means J.C., Gerdes B.C., Kaja S., Sumien N., Payne A.J., Stark D.A., Borden P.K., Price J.L., Koulen P. Caspase-3-Dependent Proteolytic Cleavage of Tau Causes Neurofibrillary Tangles and Results in Cognitive Impairment During Normal Aging. Neurochem. Res. 2016;41:2278&#x2013;2288. doi: 10.1007/s11064-016-1942-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-1942-9</ArticleId><ArticleId IdType="pmc">PMC4965284</ArticleId><ArticleId IdType="pubmed">27220334</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H., Albrecht S., Bourdeau M., Petzke T., Bergeron C., LeBlanc A.C. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer&#x2019;s disease. Am. J. Pathol. 2004;165:523&#x2013;531. doi: 10.1016/S0002-9440(10)63317-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63317-2</ArticleId><ArticleId IdType="pmc">PMC1618555</ArticleId><ArticleId IdType="pubmed">15277226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramcharitar J., Albrecht S., Afonso V.M., Kaushal V., Bennett D.A., Leblanc A.C. Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. J. Neuropathol. Exp. Neurol. 2013;72:824&#x2013;832. doi: 10.1097/NEN.0b013e3182a0a39f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182a0a39f</ArticleId><ArticleId IdType="pmc">PMC3777607</ArticleId><ArticleId IdType="pubmed">23965742</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.Y., Ferreira A. The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J. Neurosci. 2005;25:5365&#x2013;5375. doi: 10.1523/JNEUROSCI.1125-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1125-05.2005</ArticleId><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto S.E., Motoi Y., Ishiguro K., Tabira T., Kametani F., Hasegawa M., Hattori N. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: Implications of prion-like properties. Hum. Mol. Genet. 2015;24:6403&#x2013;6416. doi: 10.1093/hmg/ddv351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv351</ArticleId><ArticleId IdType="pubmed">26374846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishizen-Eberz A.J., Guttmann R.P., Giasson B.I., Day G.A., 3rd, Hodara R., Ischiropoulos H., Lee V.M., Trojanowski J.Q., Lynch D.R. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 2003;86:836&#x2013;847. doi: 10.1046/j.1471-4159.2003.01878.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01878.x</ArticleId><ArticleId IdType="pubmed">12887682</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson&#x2019;s disease-linked mutations. Proc. Natl. Acad. Sci. USA. 2005;102:2162&#x2013;2167. doi: 10.1073/pnas.0406976102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0406976102</ArticleId><ArticleId IdType="pmc">PMC548541</ArticleId><ArticleId IdType="pubmed">15684072</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., Thomas P.J. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease. J. Biol. Chem. 2005;280:22670&#x2013;22678. doi: 10.1074/jbc.M501508200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501508200</ArticleId><ArticleId IdType="pubmed">15840579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O&#x2019;Connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M., et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): Implications for Lewy body disorders. J. Neurosci. 2006;26:3942&#x2013;3950. doi: 10.1523/JNEUROSCI.4965-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4965-05.2006</ArticleId><ArticleId IdType="pmc">PMC6673887</ArticleId><ArticleId IdType="pubmed">16611810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Nguyen L.T., Burlak C., Chegini F., Guo F., Chataway T., Ju S., Fisher O.S., Miller D.W., Datta D., et al. Caspase-1 causes truncation and aggregation of the Parkinson&#x2019;s disease-associated protein alpha-synuclein. Proc. Natl. Acad. Sci. USA. 2016;113:9587&#x2013;9592. doi: 10.1073/pnas.1610099113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1610099113</ArticleId><ArticleId IdType="pmc">PMC5003239</ArticleId><ArticleId IdType="pubmed">27482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Xu Y.F., Cook C., Gendron T.F., Roettges P., Link C.D., Lin W.L., Tong J., Castanedes-Casey M., Ash P., et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2009;106:7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Xu Y.F., Dickey C.A., Buratti E., Baralle F., Bailey R., Pickering-Brown S., Dickson D., Petrucelli L. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J. Neurosci. 2007;27:10530&#x2013;10534. doi: 10.1523/JNEUROSCI.3421-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3421-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L.L., Che M.X., Zhao J., Zhou C.J., Xie M.Y., Li H.Y., He J.H., Hu H.Y. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J. Biol. Chem. 2013;288:19614&#x2013;19624. doi: 10.1074/jbc.M113.463828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.463828</ArticleId><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J., Xu W., Jin N., Li L., Zhou Y., Chu D., Gong C.X., Iqbal K., Liu F. Truncation of Tau selectively facilitates its pathological activities. J. Biol. Chem. 2020;295:13812&#x2013;13828. doi: 10.1074/jbc.RA120.012587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.012587</ArticleId><ArticleId IdType="pmc">PMC7535906</ArticleId><ArticleId IdType="pubmed">32737201</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimoto Y., Ito D., Yagi T., Nihei Y., Tsunoda Y., Suzuki N. Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J. Biol. Chem. 2010;285:608&#x2013;619. doi: 10.1074/jbc.M109.022012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.022012</ArticleId><ArticleId IdType="pmc">PMC2804209</ArticleId><ArticleId IdType="pubmed">19887443</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning B.A., Walker A.K. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Front. Neurosci. 2019;13:335. doi: 10.3389/fnins.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003;26:267&#x2013;298. doi: 10.1146/annurev.neuro.26.010302.081142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.26.010302.081142</ArticleId><ArticleId IdType="pubmed">12704221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadad B.S., Britton G.B., Rao K.S. Targeting oligomers in neurodegenerative disorders: Lessons from alpha-synuclein, tau, and amyloid-beta peptide. J. Alzheimers Dis. 2011;24((Suppl. S2)):223&#x2013;232. doi: 10.3233/JAD-2011-110182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-110182</ArticleId><ArticleId IdType="pubmed">21460436</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe C.G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging. 2006;27:570&#x2013;575. doi: 10.1016/j.neurobiolaging.2005.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.04.017</ArticleId><ArticleId IdType="pubmed">16481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaran R.N., Serpell L.C. Amyloid fibrils: Abnormal protein assembly. Prion. 2008;2:112&#x2013;117. doi: 10.4161/pri.2.3.7488.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.2.3.7488</ArticleId><ArticleId IdType="pmc">PMC2634529</ArticleId><ArticleId IdType="pubmed">19158505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I., Karran E., De Strooper B. The toxic Abeta oligomer and Alzheimer&#x2019;s disease: An emperor in need of clothes. Nat. Neurosci. 2012;15:349&#x2013;357. doi: 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Breydo L., Uversky V.N. Structural, morphological, and functional diversity of amyloid oligomers. FEBS Lett. 2015;589:2640&#x2013;2648. doi: 10.1016/j.febslet.2015.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.07.013</ArticleId><ArticleId IdType="pubmed">26188543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S.E. Toxic oligomer species of amyloid-beta in Alzheimer&#x2019;s disease, a timing issue. Swiss Med. Wkly. 2014;144:w14021. doi: 10.4414/smw.2014.14021.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2014.14021</ArticleId><ArticleId IdType="pmc">PMC5858692</ArticleId><ArticleId IdType="pubmed">25375761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura S., Shinoda K., Yamada M., Yokojima S., Inoue M., Ohnishi T., Shimada T., Kikuchi K., Masui D., Hashimoto S., et al. Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J. Biol. Chem. 2011;286:11555&#x2013;11562. doi: 10.1074/jbc.M110.181313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.181313</ArticleId><ArticleId IdType="pmc">PMC3064209</ArticleId><ArticleId IdType="pubmed">21292768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., et al. Synaptic targeting by Alzheimer&#x2019;s-related amyloid beta oligomers. J. Neurosci. 2004;24:10191&#x2013;10200. doi: 10.1523/JNEUROSCI.3432-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3432-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer&#x2019;s disease. J. Neurosci. 2007;27:796&#x2013;807. doi: 10.1523/JNEUROSCI.3501-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3501-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco P.T., Heffern M.C., Sebollela A., Popova I.A., Lacor P.N., Lee K.B., Sun X., Tiano B.N., Viola K.L., Eckermann A.L., et al. Synapse-binding subpopulations of Abeta oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem. Neurosci. 2012;3:972&#x2013;981. doi: 10.1021/cn300122k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn300122k</ArticleId><ArticleId IdType="pmc">PMC3503444</ArticleId><ArticleId IdType="pubmed">23173076</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P., Reed M.N., Kotilinek L.A., Grant M.K., Forster C.L., Qiang W., Shapiro S.L., Reichl J.H., Chiang A.C., Jankowsky J.L., et al. Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration. Cell Rep. 2015;11:1760&#x2013;1771. doi: 10.1016/j.celrep.2015.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.05.021</ArticleId><ArticleId IdType="pmc">PMC4494129</ArticleId><ArticleId IdType="pubmed">26051935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999;19:8876&#x2013;8884. doi: 10.1523/JNEUROSCI.19-20-08876.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.19-20-08876.1999</ArticleId><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A., Englund H., Soderberg L., Tucker S., Clausen F., Hillered L., Gordon M., Morgan D., Lannfelt L., Pettersson F.E., et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer&#x2019;s disease transgenic mice. FEBS J. 2009;276:995&#x2013;1006. doi: 10.1111/j.1742-4658.2008.06836.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06836.x</ArticleId><ArticleId IdType="pmc">PMC2752010</ArticleId><ArticleId IdType="pubmed">19215301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C.A., Kayed R. Astrocytes contain amyloid-beta annular protofibrils in Alzheimer&#x2019;s disease brains. FEBS Lett. 2011;585:3052&#x2013;3057. doi: 10.1016/j.febslet.2011.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2011.08.027</ArticleId><ArticleId IdType="pubmed">21872592</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson J., Castillo-Carranza D.L., Sengupta U., Bodani R., Prough D.S., DeWitt D.S., Hawkins B.E., Kayed R. Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. J. Neurotrauma. 2016;33:2034&#x2013;2043. doi: 10.1089/neu.2015.4262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2015.4262</ArticleId><ArticleId IdType="pmc">PMC5116695</ArticleId><ArticleId IdType="pubmed">26729399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins B.E., Krishnamurthy S., Castillo-Carranza D.L., Sengupta U., Prough D.S., Jackson G.R., DeWitt D.S., Kayed R. Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: Possible link between traumatic brain injury and sporadic tauopathies. J. Biol. Chem. 2013;288:17042&#x2013;17050. doi: 10.1074/jbc.M113.472746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.472746</ArticleId><ArticleId IdType="pmc">PMC3675635</ArticleId><ArticleId IdType="pubmed">23632019</ArticleId></ArticleIdList></Reference><Reference><Citation>Himmelstein D.S., Ward S.M., Lancia J.K., Patterson K.R., Binder L.I. Tau as a therapeutic target in neurodegenerative disease. Pharmacol. Ther. 2012;136:8&#x2013;22. doi: 10.1016/j.pharmthera.2012.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2012.07.001</ArticleId><ArticleId IdType="pmc">PMC3697479</ArticleId><ArticleId IdType="pubmed">22790092</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A. Tauopathies and tau oligomers. J. Alzheimers Dis. 2013;37:565&#x2013;568. doi: 10.3233/JAD-130653.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130653</ArticleId><ArticleId IdType="pubmed">23948895</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S., Sahara N., Saito Y., Murayama S., Ikai A., Takashima A. Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer&#x2019;s disease. Neurosci. Res. 2006;54:197&#x2013;201. doi: 10.1016/j.neures.2005.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2005.11.009</ArticleId><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg M.S., Lansbury P.T., Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson&#x2019;s disease? Nat. Cell Biol. 2000;2:E115&#x2013;E119. doi: 10.1038/35017124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017124</ArticleId><ArticleId IdType="pubmed">10878819</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T., Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson&#x2019;s disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA. 2000;97:571&#x2013;576. doi: 10.1073/pnas.97.2.571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.2.571</ArticleId><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosa M.M., Ferreon J.C., Ferreon A.C.M. Single-Molecule FRET Detection of Early-Stage Conformations in alpha-Synuclein Aggregation. Methods Mol. Biol. 2019;1948:221&#x2013;233. doi: 10.1007/978-1-4939-9124-2_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9124-2_17</ArticleId><ArticleId IdType="pubmed">30771181</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearborn A.D., Wall J.S., Cheng N., Heymann J.B., Kajava A.V., Varkey J., Langen R., Steven A.C. alpha-Synuclein Amyloid Fibrils with Two Entwined, Asymmetrically Associated Protofibrils. J. Biol. Chem. 2016;291:2310&#x2013;2318. doi: 10.1074/jbc.M115.698787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.698787</ArticleId><ArticleId IdType="pmc">PMC4732214</ArticleId><ArticleId IdType="pubmed">26644467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T., Jr. Alpha-synuclein, especially the Parkinson&#x2019;s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002;322:1089&#x2013;1102. doi: 10.1016/S0022-2836(02)00735-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(02)00735-0</ArticleId><ArticleId IdType="pubmed">12367530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Caulfield T., Xu Y.F., Gendron T.F., Hubbard J., Stetler C., Sasaguri H., Whitelaw E.C., Cai S., Lee W.C., et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum. Mol. Genet. 2013;22:3112&#x2013;3122. doi: 10.1093/hmg/ddt166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt166</ArticleId><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T., Hock E.M., Ernst P., Foglieni C., Jambeau M., Gilhespy L.A.B., Laferriere F., Maniecka Z., Pluckthun A., Mittl P., et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun. 2017;8:45. doi: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoi P.S., Choi K.J., Leonard P.G., Sizovs A., Moosa M.M., MacKenzie K.R., Ferreon J.C., Ferreon A.C.M. The N-Terminal Domain of ALS-Linked TDP-43 Assembles without Misfolding. Angew. Chem. Int. Ed. Engl. 2017;56:12590&#x2013;12593. doi: 10.1002/anie.201706769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201706769</ArticleId><ArticleId IdType="pubmed">28833982</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiina Y., Arima K., Tabunoki H., Satoh J. TDP-43 dimerizes in human cells in culture. Cell. Mol. Neurobiol. 2010;30:641&#x2013;652. doi: 10.1007/s10571-009-9489-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-009-9489-9</ArticleId><ArticleId IdType="pubmed">20043239</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y.S., Tsai K.J., Chang Y.J., Kao P., Woods R., Kuo P.H., Wu C.C., Liao J.Y., Chou S.C., Lin V., et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat. Commun. 2014;5:4824. doi: 10.1038/ncomms5824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5824</ArticleId><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman A.A., Weber C.A., Julicher F. Liquid-liquid phase separation in biology. Annu. Rev. Cell Dev. Biol. 2014;30:39&#x2013;58. doi: 10.1146/annurev-cellbio-100913-013325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100913-013325</ArticleId><ArticleId IdType="pubmed">25288112</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudyal R.R., Pir Cakmak F., Keating C.D., Bevilacqua P.C. Physical Principles and Extant Biology Reveal Roles for RNA-Containing Membraneless Compartments in Origins of Life Chemistry. Biochemistry. 2018;57:2509&#x2013;2519. doi: 10.1021/acs.biochem.8b00081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.8b00081</ArticleId><ArticleId IdType="pmc">PMC7276092</ArticleId><ArticleId IdType="pubmed">29560725</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne C.P., Eckmann C.R., Courson D.S., Rybarska A., Hoege C., Gharakhani J., Julicher F., Hyman A.A. Germline P granules are liquid droplets that localize by controlled dissolution/condensation. Science. 2009;324:1729&#x2013;1732. doi: 10.1126/science.1172046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1172046</ArticleId><ArticleId IdType="pubmed">19460965</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R., Choi K.J., Quan M.D., Sharma S., Sankaran B., Park H., LaGrone A., Kim J.J., MacKenzie K.R., Ferreon A.C.M., et al. Liquid condensation of reprogramming factor KLF4 with DNA provides a mechanism for chromatin organization. Nat. Commun. 2021;12:5579. doi: 10.1038/s41467-021-25761-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25761-7</ArticleId><ArticleId IdType="pmc">PMC8458463</ArticleId><ArticleId IdType="pubmed">34552088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Vega A., Braun M., Scharrel L., Jahnel M., Wegmann S., Hyman B.T., Alberti S., Diez S., Hyman A.A. Local Nucleation of Microtubule Bundles through Tubulin Concentration into a Condensed Tau Phase. Cell Rep. 2017;20:2304&#x2013;2312. doi: 10.1016/j.celrep.2017.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.042</ArticleId><ArticleId IdType="pmc">PMC5828996</ArticleId><ArticleId IdType="pubmed">28877466</ArticleId></ArticleIdList></Reference><Reference><Citation>Protter D.S.W., Parker R. Principles and Properties of Stress Granules. Trends Cell Biol. 2016;26:668&#x2013;679. doi: 10.1016/j.tcb.2016.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2016.05.004</ArticleId><ArticleId IdType="pmc">PMC4993645</ArticleId><ArticleId IdType="pubmed">27289443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambadipudi S., Biernat J., Riedel D., Mandelkow E., Zweckstetter M. Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. Nat. Commun. 2017;8:275. doi: 10.1038/s41467-017-00480-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00480-0</ArticleId><ArticleId IdType="pmc">PMC5561136</ArticleId><ArticleId IdType="pubmed">28819146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawner A.S., Ray S., Yadav P., Mukherjee S., Panigrahi R., Poudyal M., Patel K., Ghosh D., Kummerant E., Kumar A., et al. Modulating alpha-Synuclein Liquid-Liquid Phase Separation. Biochemistry. 2021;60:3676&#x2013;3696. doi: 10.1021/acs.biochem.1c00434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.1c00434</ArticleId><ArticleId IdType="pubmed">34431665</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A., Temirov J., Lee J., Coughlin M., Kanagaraj A.P., Kim H.J., Mittag T., Taylor J.P. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133. doi: 10.1016/j.cell.2015.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.015</ArticleId><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuffner A.M., Linsenmeier M., Grigolato F., Prodan M., Zuccarini R., Capasso Palmiero U., Faltova L., Arosio P. Sequestration within biomolecular condensates inhibits Abeta-42 amyloid formation. Chem. Sci. 2021;12:4373&#x2013;4382. doi: 10.1039/D0SC04395H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0SC04395H</ArticleId><ArticleId IdType="pmc">PMC8179469</ArticleId><ArticleId IdType="pubmed">34163700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Hwo S.Y., Kirschner M.W. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 1977;116:207&#x2013;225. doi: 10.1016/0022-2836(77)90213-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(77)90213-3</ArticleId><ArticleId IdType="pubmed">599557</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S., Eftekharzadeh B., Tepper K., Zoltowska K.M., Bennett R.E., Dujardin S., Laskowski P.R., MacKenzie D., Kamath T., Commins C., et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 2018;37:e98049. doi: 10.15252/embj.201798049.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798049</ArticleId><ArticleId IdType="pmc">PMC5881631</ArticleId><ArticleId IdType="pubmed">29472250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreon J., Jain A., Choi K.-J., Tsoi P., MacKenzie K., Jung S., Ferreon A. Acetylation Disfavors Tau Phase Separation. Int. J. Mol. Sci. 2018;19:1360. doi: 10.3390/ijms19051360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051360</ArticleId><ArticleId IdType="pmc">PMC5983838</ArticleId><ArticleId IdType="pubmed">29734651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S., Singh N., Kumar R., Patel K., Pandey S., Datta D., Mahato J., Panigrahi R., Navalkar A., Mehra S., et al. alpha-Synuclein aggregation nucleates through liquid-liquid phase separation. Nat. Chem. 2020;12:705&#x2013;716. doi: 10.1038/s41557-020-0465-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41557-020-0465-9</ArticleId><ArticleId IdType="pubmed">32514159</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak W.M., Haider R., Dumm B.K., Sarkar P., Surewicz K., Choi J.K., Surewicz W.K. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain. J. Biol. Chem. 2019;294:6306&#x2013;6317. doi: 10.1074/jbc.RA118.007222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.007222</ArticleId><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi K.J., Tsoi P.S., Moosa M.M., Paulucci-Holthauzen A., Liao S.J., Ferreon J.C., Ferreon A.C.M. A Chemical Chaperone Decouples TDP-43 Disordered Domain Phase Separation from Fibrillation. Biochemistry. 2018;57:6822&#x2013;6826. doi: 10.1021/acs.biochem.8b01051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.8b01051</ArticleId><ArticleId IdType="pmc">PMC6555487</ArticleId><ArticleId IdType="pubmed">30520303</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella A.E., Zerze G.H., Mittal J., Fawzi N.L. ALS Mutations Disrupt Phase Separation Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Structure. 2016;24:1537&#x2013;1549. doi: 10.1016/j.str.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>